BMJ:ACEI为糖尿病患者**降压药

2013-10-30 蔡晓峰 医学界网站

我国台湾学者简国龙、杜裕康等新近发表的一项荟萃分析显示,血管紧张素转换酶抑制剂(ACEI)在成年糖尿病患者中是首选的抗高血压治疗药物。该研究发表于10月24日的《英国医学杂志》(BMJ)。   研究人员通过对PubMed、Medline、Scopus、Cochrane等数据的检索,分析了63项随机试验。这些试验在近37,000位患有糖尿病的成年人中评价了11种不同的降压治疗方案。研究终点

我国台湾学者简国龙、杜裕康等新近发表的一项荟萃分析显示,血管紧张素转换酶抑制剂(ACEI)在成年糖尿病患者中是首选的抗高血压治疗药物。该研究发表于10月24日的《英国医学杂志》(BMJ【原文下载】。  

研究人员通过对PubMed、Medline、Scopus、Cochrane等数据的检索,分析了63项随机试验。这些试验在近37,000位患有糖尿病的成年人中评价了11种不同的降压治疗方案。研究终点包括全因死亡率、终末期肾病,以及血清肌酐水平倍增。  

结果显示:ACEI加钙通道阻滞剂联合治疗最有可能降低全因死亡率;β受体阻滞剂则显示死亡率明显上升。与安慰剂相比,只有ACEI能显著预防血清肌酐水平倍增的终点事件。ACEI与血管紧张素受体阻滞剂(ARB)的结果无显著差异,但作者指出,ACEI“在所有研究终点中获得较优排名的概率都较高”。  

作者认为,现有证据未显示ARB类药物效果优于ACEI,考虑到医疗成本,ACEI应该是成年糖尿病患者的一线抗高血压治疗药物,并指出在单用ACEI不能控制血压时,可加用钙通道阻滞剂。  

原文出处:

Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL.Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.BMJ. 2013 Oct 24;347:f6008. doi: 10.1136/bmj.f6008.【原文下载】


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655689, encodeId=d50a165568908, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Jan 07 03:06:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847522, encodeId=4704184e5221b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Apr 01 03:06:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291804, encodeId=75491291804c8, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473752, encodeId=9b0d14e37520d, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=)]
    2014-01-07 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655689, encodeId=d50a165568908, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Jan 07 03:06:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847522, encodeId=4704184e5221b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Apr 01 03:06:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291804, encodeId=75491291804c8, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473752, encodeId=9b0d14e37520d, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=)]
    2014-04-01 gaoxiaoe
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655689, encodeId=d50a165568908, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Jan 07 03:06:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847522, encodeId=4704184e5221b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Apr 01 03:06:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291804, encodeId=75491291804c8, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473752, encodeId=9b0d14e37520d, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655689, encodeId=d50a165568908, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Jan 07 03:06:00 CST 2014, time=2014-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847522, encodeId=4704184e5221b, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Tue Apr 01 03:06:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291804, encodeId=75491291804c8, content=<a href='/topic/show?id=9d32981418b' target=_blank style='color:#2F92EE;'>#降压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98141, encryptionId=9d32981418b, topicName=降压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f14236, createdName=经常头晕, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473752, encodeId=9b0d14e37520d, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 01 01:06:00 CST 2013, time=2013-11-01, status=1, ipAttribution=)]

相关资讯

JACC Heart Failure:ACEI联合硝酸酯有望改善心衰患者转归

  在心衰患者中,血管紧张素转化酶抑制剂(ACEI)和硝酸酯类药物联合治疗可消除肼屈嗪需求,降低硝酸酯类药物耐药,并改善患者转归。综述于6月3日发表于《美国心脏病学会杂志:心衰》(JACC:Heart Failure)。   此项综述评述了心衰患者应用硝酸酯治疗的相关证据,以及克服硝酸酯耐药和未来硝酸酯治疗临床试验设计的策略。综述同时明确了肼屈嗪治疗的获益和局限,ACEI对硝酸酯耐药的

PAS 2013:儿童高血压或影响其认知

  华盛顿——美国罗切斯特大学医学中心的小儿肾病专家Marc Lande医生在儿科学术学会(PAS)2013年会上报告了一项仍在进行中的研究的初步结果:患有高血压的儿童具有较差的注意力和语言、视觉记忆力。而且较低的社会经济地位似乎会放大这种效应,使高血压患儿的认知问题变得更严重。   他在接受采访时表示:“这些初步数据并未告诉我们为何会有这些差异,有可能是高血压本身导致的,因为我们知道大脑是高血

EHJ:荟萃分析显示降低高血压死亡率ACEI优于ARBs

       Laura C van Vark博士(荷兰伊拉斯姆斯大学医学中心)和他的同事在他们发表于2012年4月17日《欧洲心脏病杂志》[European heart journal.2012-04-17.]的一项新的荟萃分析表明,与同一时期的应用非ACEI类药物或血管紧张素受体阻滞剂等药物(ARBs)的患者相比应用ACEI类药物的高血压患者的全死因死亡

FDA更新含阿利吉仑降压药安全性标签

  4月20日,美国食品与药物管理局(FDA)发布公告称,若将含阿利吉仑的抗高血压药与血管紧张素转换酶抑制剂(ACEI)或血管紧张素Ⅱ受体阻滞剂(ARB)联用,则糖尿病及有中重度肾损伤患者具有发生肾损伤、低血压及高钾血症的风险,因此应避免使用。但在未咨询医师的情况下,正在接受含阿利吉仑药物治疗的患者不应擅自停用该类药物。   须修改安全性标签的药物有:① Amturnide(阿利吉仑/

Hypertension:无糖尿病患者ACEI与小剂量噻嗪利尿剂联用对胰岛素作用影响不大

到目前为止关于降压治疗最大临床研究(Lipid-Lowering Treatment to Prevent Heart Attack Trial ,ALLHAT)发现利尿剂在降低某些心血管结局上优于其他降压药,但是与ACE抑制剂及钙离子拮抗剂相比,利尿剂增加新发2型糖尿病风险。来自北爱尔兰的研究人员McHenry CM等曾早些时候发现ACE抑制剂对胰岛素的作用是中性的。与单用ACE抑制相比,高剂量

Neurology:降压药或可降低阿尔茨海默病发病风险

认知功能正常或轻微认知功能障碍(MCI)患者,使用利尿剂、血管紧张素1受体阻滞剂(ARB)、血管紧张素转化酶抑制剂(ACEI)、钙通道阻滞剂(CCB)或β受体阻滞剂(BB)是否与阿尔茨海默病(AD)痴呆风险下降相关尚不清楚。为此,美国约翰斯霍普金斯大学SevilYasar等人进行了一项研究,研究结果在线发表在2013年8月2日的Neurology杂志上。研究结果提示:利尿剂、ARB和ACEI的应用